ABSTRACT
Dynamic contrast-enhanced computed tomography (CT) techniques have been the subject of resurgent interest in recent years due to an evolving need for in vivo assessment of tumor angiogenesis on an individual patient basis. CT has many advantages over other imaging methods. It is widely available, provides excellent anatomical detail and quantification of tumor perfusion, blood volume and vascular leakage by Food and Drug Administration (FDA) approved user-friendly commercial software is straightforward ( Table 64.1 ). Vascular estimates have been correlated with histological angiogenesis markers. The latest high-end multidetector row CT systems are capable of rapid scanning and large volume coverage enabling entire tumors to be evaluated.
